Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Chapman, Rosamund ^a   Stutz, Helen ^a   Jacobs Jr , William ^a   Shephard, Enid ^a,b,c   Williamson, Anna Lise ^a,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; EPITOPE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; INTERLEUKIN 2; NEF PROTEIN; RECOMBINANT BCG VACCINE; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA; RECOMBINANT VACCINE; RNA DIRECTED DNA POLYMERASE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUXOTROPHY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG STABILITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSTIMULATION; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; VACCINATION; VECTOR CONTROL; VIRUS ENVELOPE; VIRUS STRAIN; WILD TYPE;

ANIMALS; BCG VACCINE; CROSS-PRIMING; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; PANTOTHENIC ACID; RNA-DIRECTED DNA POLYMERASE; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 84882580550     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071601     Document Type: Article

References (38)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
2. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286.
3. Ndhlovu ZM, Proudfoot J, Cesa K, Alvino DM, McMullen A, et al. (2012) Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. J Virol 86: 6959-6969.
4. Cayabyab MJ, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, et al. (2009) Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol 83: 5505-5513.
5. Chapman R, Shephard E, Stutz H, Douglass N, Sambandamurthy V, et al. (2012) Priming with a Recombinant Pantothenate Auxotroph of Mycobacterium bovis BCG and Boosting with MVA Elicits HIV-1 Gag Specific CD8(+) T Cells. PLoS One 7: e32769.
6. Hopkins R, Bridgeman A, Bourne C, Mbewe-Mwula A, Sadoff JC, et al. (2011) Optimizing HIV-1-specific CD8(+) T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol 41: 3542-3552.
7. Im EJ, Saubi N, Virgili G, Sander C, Teoh D, et al. (2007) Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol 81: 9408-9418.
8. Rosario M, Hopkins R, Fulkerson J, Borthwick N, Quigley MF, et al. (2010) Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J Virol 84: 5898-5908.
9. Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, et al. (2006) Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity (vol 79, pg 12871, 2005). Journal of Virology 80: 10288.
10. Chege GK, Burgers WA, Stutz H, Meyers AE, Chapman R, et al. (2013) Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. J Virol 87: 5151-5160.
11. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA, (2008) A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect Immun 76: 5200-5214.
12. Eisenhut M, Paranjothy S, Abubakar I, Bracebridge S, Lilley M, et al. (2009) BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine 27: 6116-6120.
13. Soysal A, Millington KA, Bakir M, Dosanjh D, Aslan Y, (2005) Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366: 1443-1451.
14. Roy RB, Sotgiu G, Altet-Gomez N, Tsolia M, Ruga E, et al. (2012) Identifying predictors of interferon-gamma release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study. Am J Respir Crit Care Med 186: 378-384.
15. Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, et al. (2003) Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses 19: 133-144.
16. Burgers WA, Shephard E, Monroe JE, Greenhalgh T, Binder A, et al. (2008) Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses. 24: 195-206.
17. Williamson AL, Rybiki E, Shephard E, Gray G, Bekker LG, et al. (2012) South African HIV-1 vaccine candidates - the journey from the bench to clinical trials. S Afr Med J 102: 452-455.
18. Burgers WA, van Harmelen JH, Shephard E, Adams C, Mgwebi T, et al. (2006) Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol 87: 399-410.
19. Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, et al. (1988) An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 85: 3105-3109.
20. Zahrt TC, Deretic V, (2000) An essential two-component signal transduction system in Mycobacterium tuberculosis. J Bacteriol 182: 3832-3838.
21. Parish T, Stoker NG (1998) Electroporation of mycobacteria. In: Parish T, Stoker NG, editors. Mycobacterium tuberculosis Protocols. Totowa, New Jersey: Humana Press Inc. 129-144.
22. Mata M, Travers PJ, Liu Q, Frankel FR, Paterson Y, (1998) The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J Immunol. 161: 2985-2993.
23. Mata M, Paterson Y, (1999) Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. J Immunol 163: 1449-1456.
24. van Harmelen JH, Shephard E, Thomas R, Hanke T, Williamson AL, et al. (2003) Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine 21: 4380-4389.
25. Shephard E, Burgers WA, van Harmelen JH, Monroe JE, Greenhalgh T, et al. (2008) A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res Hum Retroviruses 24: 207-217.
26. Russell MS, Iskandar M, Mykytczuk OL, Nash JH, Krishnan L, et al. (2007) A reduced antigen load in vivo, rather than weak inflammation, causes a substantial delay in CD8+ T cell priming against Mycobacterium bovis (bacillus Calmette-Guerin). J Immunol 179: 211-220.
27. Russell MS, Dudani R, Krishnan L, Sad S, (2009) IFN-gamma expressed by T cells regulates the persistence of antigen presentation by limiting the survival of dendritic cells. J Immunol 183: 7710-7718.
28. Sad S, Dudani R, Gurnani K, Russell M, van Faassen H, et al. (2008) Pathogen proliferation governs the magnitude but compromises the function of CD8 T cells. J Immunol 180: 5853-5861.
29. van Faassen H, Saldanha M, Gilbertson D, Dudani R, Krishnan L, et al. (2005) Reducing the stimulation of CD8+ T cells during infection with intracellular bacteria promotes differentiation primarily into a central (CD62LhighCD44high) subset. J Immunol 174: 5341-5350.
30. van Faassen H, Dudani R, Krishnan L, Sad S, (2004) Prolonged antigen presentation, APC-, and CD8(+) T cell turnover during mycobacterial infection: Comparison with Listeria monocytogenes. Journal of Immunology 172: 3491-3500.
31. Hopkins R, Bridgeman A, Joseph J, Gilbert SC, McShane H, et al. (2011) Dual neonate vaccine platform against HIV-1 and M. tuberculosis. PLoS One 6: e20067.
32. Joseph J, Fernandez-Lloris R, Pezzat E, Saubi N, Cardona PJ, et al. (2010) Molecular characterization of heterologous HIV-1gp120 gene expression disruption in Mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors. J Biomed Biotechnol 2010: 357370.
33. Mederle I, Le Grand R, Vaslin B, Badell E, Vingert B, et al. (2003) Mucosal administration of three recombinant Mycobacterium bovis BCG-SIVmac251 strains to cynomolgus macaques induces rectal IgAs and boosts systemic cellular immune responses that are primed by intradermal vaccination. Vaccine 21: 4153-4166.
34. Rodriguez F, Harkins S, Slifka MK, Whitton JL, (2002) Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. Journal of Virology 76: 4251-4259.
35. Neyrolles O, Gould K, Gares MP, Brett S, Janssen R, et al. (2001) Lipoprotein access to MHC class I presentation during infection of murine macrophages with live mycobacteria. J Immunol 166: 447-457.
36. Ferrando-Martinez S, Casazza JP, Leal M, Machmach K, Munoz-Fernandez MA, et al. (2012) Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers. J Virol 86: 3667-3674.
37. Letvin NL, (2006) Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 6: 930-939.
38. Mattapallil JJ, Hill B, Douek DC, Roederer M, (2006) Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge. J Med Primatol 35: 217-224.